Ohio is currently home to 3190 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/09/2024
Locations: Site #447, Beavercreek, Ohio
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Register for Updates
A Registry for People With T-cell Lymphoma
NCT05978141
Recruiting
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Ohio State University (Data Collection Only), Columbus, Ohio
Conditions: T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Register for Updates
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
NCT05750498
Recruiting
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative. Pediatric Autoimmune Hepatitis (AIH) and Primary Scleros... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
NCT05556642
Recruiting
There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with rrHBL, prospectively. Cases are identified through: 1. Existing clinical and/or ca... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Relapsed Hepatoblastoma, Refractory Hepatoblastoma
Register for Updates
Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT05320198
Recruiting
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Register for Updates
INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
NCT05277272
Recruiting
The purpose of this observational study is to collect data on the natural history of disease of patients with Hemophagocytic Lymphohistiocytosis (HLH) including diagnosis, treatments, responses, and outcomes.
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hemophagocytic Lymphohistiocytoses
Register for Updates
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
NCT05113368
Recruiting
To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Ovarian Cancer, Serous Ovarian Cancer
Register for Updates
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
NCT05020535
Recruiting
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Intracerebral Hemorrhage
Register for Updates
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center - PIN, Cincinnati, Ohio
Conditions: Chronic Migraine in Children
Register for Updates
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
NCT04908735
Recruiting
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy, and lung injury affects as many as 25% of children receiving HSCT. Improved transplant techniques and major improvements in survival mean that HSCT is being more widely used, and more mismatched grafts are being used. Bronchiolitis obliterans (BO) is a major limitation of pediatric HSCT success as BO is commonly diagnosed late in children, when lung injury is irreversible, leading to long term morbidity or even death. C... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO)
Register for Updates
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
NCT04098445
Recruiting
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently need... Read More
Gender:
ALL
Ages:
24 years and below
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis, Bronchiolitis Obliterans
Register for Updates
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: University of Cincinnati (UC) Waddell Center for Multiple Sclerosis, Cincinnati, Ohio
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates